Abbonarsi

Prevalence of anemia and effects on mortality in patients with heart failure - 21/08/11

Doi : 10.1016/j.ahj.2004.08.039 
JoAnn Lindenfeld, MD, FACC
Cardiac Transplantation Program and the Center for Women's Health Research, University of Colorado Health Sciences Center, Denver, Colo 

 Reprint requests: JoAnn Lindenfeld, MD, FACC, Cardiac Transplantation Program, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box B130, Denver, CO 80262.

Riassunto

Background

In patients with chronic kidney disease, the adverse cardiovascular effects of anemia have been well established. New data are emerging to suggest anemia may represent an important treatable cause of cardiac morbidity and mortality in patients with heart failure. To improve the understanding of the problem of anemia in heart failure, it is important to assess the factors that influence the prevalence of anemia and to assess the consistency of the association of anemia and mortality in various populations of patients with heart failure.

Methods

A systematic review of the literature was conducted by performing detailed searches of MEDLINE and EMBASE, searching the bibliographies of the articles retrieved during the database search, and conferring with heart-failure experts involved in clinical trials.

Twenty-eight publications from 26 studies that evaluated anemia prevalence with or without effects on mortality in patients with heart failure were identified. The definition of anemia used in each study was tabulated along with pertinent patient characteristics, the prevalence of anemia, and the association between anemia and mortality.

Results

Anemia is common among patients with heart failure. The prevalence of anemia increases with increasing severity of heart failure, declining renal function, and increasing age. Anemia is consistently associated with poorer survival in all patient populations, but there are substantial differences in the patient populations and definition of anemia.

Conclusions

To clarify the prognostic relationship of anemia in patients with heart failure, a standard definition of anemia should be adopted accounting for the menopausal status of women. Age, severity of heart failure, evaluation of kidney function, important comorbidities, and use of angiotensin-converting-enzyme inhibitors should be included, and correctable causes of anemia should be excluded. Inclusion of these factors should allow better definition of the relationship between anemia and prognosis in patients with heart failure.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Support for this literature review and preparation of the manuscript provided by Amgen Inc.


© 2005  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 149 - N° 3

P. 391-401 - Marzo 2005 Ritorno al numero
Articolo precedente Articolo precedente
  • New-onset paroxysmal atrial fibrillation: Is permanence inevitable?
  • Kristen K. Patton, Richard L. Page
| Articolo seguente Articolo seguente
  • Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
  • Paul W. Armstrong, Peter X. Adams, Hussein R. Al-Khalidi, Christian Hamm, David Holmes, William O'Neill, Thomas G. Todaro, Alec Vahanian, Frans Van de Werf, Christopher B. Granger, on behalf of the APEX-AMI Steering Committee

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.